Monitoring rituximab in autoimmune diseases
Part of Heart & circulation, Skin clinical trials.
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these autoimmune diseases: immune thrombocytopenia, autoimmune hemolytic anemia, lupus, systemic sclerosis, rheumatoid arthritis, inflammatory myopathy, ANCA vasculitis, or cryoglobulinemic vasculitis.
- You are receiving rituximab as part of your regular treatment.
- You are not taking multiple strong immunosuppressive drugs for a difficult-to-treat disease.
- You do not have a blood cancer or another type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how rituximab affects immune cells in people with a type of kidney disease called membranous nephropathy. By studying blood samples, the researchers hope to understand why some people respond better to treatment, which could help guide future care.
This study looks at how the immune system changes after treatment with rituximab for ANCA-associated vasculitis, a rare autoimmune disease that causes inflammation of blood vessels. The goal is to better understand the effects of this maintenance therapy, which may help improve future treatment decisions.
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.
This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.
This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.
Hear when a new Autoimmune Cytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.